http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014110270-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2012-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014110270-A |
| titleOfInvention | METHOD FOR PREDICTING THE RISK OF HYPERTENSION RELATED TO ANTI-ANGIOGENIC THERAPY |
| abstract | 1. A method for determining the sensitivity of a patient to the development of hypertension associated with angiogenesis inhibitor therapy, which is bevacizumab or an antibody that binds essentially the same epitope of vascular endothelial growth factor (VEGF) as bevacizumab, the method comprising: (a) determining in a sample obtained from a patient suffering from cancer of the rs2305949 polymorphism genotype (SEQ ID NO. 3), and (b) identifying the patient as more or less sensitive to the development of hypertension associated with angi inhibitor therapy iogenesis, which is bevacizumab or an antibody that binds essentially the same VEGF epitope as bevacizumab based on the indicated genotype, where the presence of the CC genotype in the rs2305949 polymorphism (SEQ ID NO. 3) indicates that the patient is more sensitive hypertension than a patient with the CT or TT genotype in the rs2305949 polymorphism (SEQ ID NO. 3), or the presence of the CT or TT genotype in the rs2305949 polymorphism (SEQ ID NO. 3) indicates that the patient is less sensitive to the development of hypertension than a patient with the CC genotype in polymorphism rs2305949 (SEQ ID NO. 3) .2. The method of claim 1, wherein the therapy further comprises a chemotherapeutic agent or a chemotherapeutic regimen. The method according to any one of paragraphs. 1 and 2, where the angiogenesis inhibitor is administered with one or more agents selected from the group consisting of taxanes, interferon alpha, 5-fluorouracil, leucovorin, irinotecan, gemcitabine-erlotinib, and platinum-based chemotherapeutic agents. 4. The method according to claim 1, wherein the cancer is pancreatic cancer, renal cell cancer, colorectal cancer, cancer of the milk |
| priorityDate | 2011-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.